- Medicine Name: Cabenuva
- Generic Name: Cabotegravir; Rilpivirine
- Dosage Form & Strength: Injection: 200 mg/mL; 300 mg/mL
- Manufactured By: ViiV Healthcare
Cabenuva contains two drugs Cabotegravir (an HIV-1 integrase strand transfer inhibitor), and Rilpivirine (an HIV-1 non-nucleoside reverse transcriptase inhibitor). It is used as a complete regimen to treat HIV-1 infection in adults and adolescents aged 12 years and older and weighing at least 35 kg to replace the current antiretroviral therapy (ART).
Recommended Dosage: Cabenuva should be administered by a health specialist by gluteal intramuscular injection. Cabenuva injection may be initiated with oral Cabotegravir and Rilpivirine before intramuscular injections or the patient may proceed directly to this injection without an oral lead-in.
Cabenuva dosage can be injected monthly or every two months. Health specialists should discuss these 2 dosing options with the respective patients before initiating Cabenuva therapy and specify which dosing frequency would be the most apt option for the patient.
Recommended Monthly Dosing Schedule: Start treatment with Cabenuva (600 mg of cabotegravir and 900 mg of rilpivirine) on the final day of current ART or oral lead-in and continue with Cabenuva (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.
Recommended Every-2-Month Dosing Schedule: Start treatment with Cabenuva (cabotegravir 600 mg and rilpivirine 900 mg) on the final day of current ART or oral lead-in for two consecutive months and continue with Cabenuva injections every two months thereafter.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.